Table 3

Effects of aPL antibodies and control antibodies on renal histology and function

Ab↑ glomerular deposition/expression
EM
Thrombin generation and renal function
Amelioration of GEC injury and renal failure
C3FibrinTFGEC damage↑TAT↑BUN↑ACRC5aR−/− miceLow TF micePravastatin
FB1 (C′ activating Ab) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
FC1 (anti-B2GPI Ab) No No No Yes Yes Yes Yes No Yes Yes 
FD1 No No No No No No No NA NA NA 
aPL-IgG Yes Yes Yes No Yes Yes Yes Partial Yes Yes 
NH-IgG No No No No No No No NA NA NA 
Ab↑ glomerular deposition/expression
EM
Thrombin generation and renal function
Amelioration of GEC injury and renal failure
C3FibrinTFGEC damage↑TAT↑BUN↑ACRC5aR−/− miceLow TF micePravastatin
FB1 (C′ activating Ab) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
FC1 (anti-B2GPI Ab) No No No Yes Yes Yes Yes No Yes Yes 
FD1 No No No No No No No NA NA NA 
aPL-IgG Yes Yes Yes No Yes Yes Yes Partial Yes Yes 
NH-IgG No No No No No No No NA NA NA 

Effects of FC1, FB1, FD1, aPL-IgG, and NH-IgG on glomerular C3 and fibrin deposition, TF expression and synthesis, plasma thrombin antithrombin III (TAT) levels, and renal function (BUN and ACR). The last 3 columns represent the effect of genetic deletion of C5aR, genetic diminution of TF, and pravastatin treatment on endothelial injury and renal failure.

C′ indicates complement; Ab, antibody; GEC, glomerular endothelial cell; and NA, not applicable.